MX2022003611A - Carboxilatos biciclicos como moduladores de transportadores y usos de los mismos. - Google Patents

Carboxilatos biciclicos como moduladores de transportadores y usos de los mismos.

Info

Publication number
MX2022003611A
MX2022003611A MX2022003611A MX2022003611A MX2022003611A MX 2022003611 A MX2022003611 A MX 2022003611A MX 2022003611 A MX2022003611 A MX 2022003611A MX 2022003611 A MX2022003611 A MX 2022003611A MX 2022003611 A MX2022003611 A MX 2022003611A
Authority
MX
Mexico
Prior art keywords
modulators
transporters
compounds
transporter
bicyclic carboxylates
Prior art date
Application number
MX2022003611A
Other languages
English (en)
Inventor
Vincent Sandanayaka
Gregory Goreczny
Original Assignee
Nirogy Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nirogy Therapeutics Inc filed Critical Nirogy Therapeutics Inc
Publication of MX2022003611A publication Critical patent/MX2022003611A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se relaciona generalmente con el campo de los moduladores de transportadores, por ejemplo, inhibidores de transpondedores de monocarboxilato y de manera más particular con compuestos de carboxilato de enona bicíclica novedosos, la síntesis y el uso de esos compuestos y sus composiciones farmacéuticas, por ejemplo, en el tratamiento, modulación y/o prevención de condiciones fisiológicas asociadas con la actividad de los transpondedores de monocarboxilato como en el tratamiento del cáncer y otros trastornos neoplásicos, rechazo de tejidos y órganos trasplantados.
MX2022003611A 2019-09-25 2020-09-24 Carboxilatos biciclicos como moduladores de transportadores y usos de los mismos. MX2022003611A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962905606P 2019-09-25 2019-09-25
PCT/US2020/052413 WO2021061929A1 (en) 2019-09-25 2020-09-24 Bicyclic carboxylates as modulators of transporters and uses thereof

Publications (1)

Publication Number Publication Date
MX2022003611A true MX2022003611A (es) 2022-04-20

Family

ID=75166130

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003611A MX2022003611A (es) 2019-09-25 2020-09-24 Carboxilatos biciclicos como moduladores de transportadores y usos de los mismos.

Country Status (13)

Country Link
US (1) US20220281888A1 (es)
EP (1) EP4034112A4 (es)
JP (1) JP2022550314A (es)
KR (1) KR20220101078A (es)
CN (1) CN114615980A (es)
AU (1) AU2020356491A1 (es)
BR (1) BR112022005226A2 (es)
CA (1) CA3149987A1 (es)
IL (1) IL290990A (es)
MX (1) MX2022003611A (es)
TW (1) TW202126661A (es)
WO (1) WO2021061929A1 (es)
ZA (1) ZA202202619B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010089580A1 (en) * 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
EP2804852A2 (en) * 2012-01-20 2014-11-26 Regents Of The University Of Minnesota Therapeutic compounds
EP3004073A1 (en) * 2013-06-07 2016-04-13 Université catholique de Louvain 3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
JP2017538689A (ja) * 2014-11-17 2017-12-28 ニーロジョン セラピューティクス インコーポレイテッドＮｉｒｏｇｙｏｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． モノカルボン酸輸送修飾薬およびその使用
JP6725519B2 (ja) * 2015-01-22 2020-07-22 ザ スクリプス リサーチ インスティテュート 複素環式のモノカルボン酸トランスポータ阻害薬
CN112105356A (zh) * 2018-03-30 2020-12-18 尼罗根治疗有限公司 作为转运蛋白的调节剂的双环烯酮羧酸酯类化合物及其应用

Also Published As

Publication number Publication date
CN114615980A (zh) 2022-06-10
AU2020356491A1 (en) 2022-03-31
CA3149987A1 (en) 2021-04-01
EP4034112A1 (en) 2022-08-03
KR20220101078A (ko) 2022-07-19
WO2021061929A1 (en) 2021-04-01
IL290990A (en) 2022-05-01
TW202126661A (zh) 2021-07-16
US20220281888A1 (en) 2022-09-08
EP4034112A4 (en) 2023-07-12
ZA202202619B (en) 2023-12-20
JP2022550314A (ja) 2022-12-01
BR112022005226A2 (pt) 2022-06-14

Similar Documents

Publication Publication Date Title
MX2021010323A (es) Compuestos bicíclicos de heterociclilo y usos de este.
MX2022007515A (es) Inhibidores de sos1.
MX2019010848A (es) Composiciones y procedimientos para el tratamiento del cancer.
ZA202005803B (en) Bicyclic enone carboxylates as modulators of transporters and uses thereof
UA106079C2 (uk) Індукуючі апоптоз засоби для лікування злоякісної пухлини і імунних і аутоімунних захворювань
MX2013012088A (es) Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1.
MY165624A (en) N-acylsulfonamide apoptosis promoters
MY192055A (en) Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
NZ757081A (en) Somatostatin modulators and uses thereof
MX2022007155A (es) Derivados de cromano novedosos que tienen actividad de degradacion de receptor de estrogeno y usos de los mismos.
CR20220207A (es) Compuestos terapéuticos y métodos de uso
MA49339A (fr) Conjugués insuline-fc à extension oligomère
CN107406464A8 (zh) 精氨酸酶抑制剂及其治疗用途
PH12021550872A1 (en) Therapeutic compounds
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
MX2022014925A (es) Moduladores de il-17a.
MX2020007586A (es) Proceso de fabricacion de moduladores de somatostatina.
MX2022014924A (es) Moduladores de il-17a.
MX2020012107A (es) Composiciones y procedimientos para el tratamiento del cancer.
WO2017136731A8 (en) Rapaglutins, novel inhibitors of glut and use thereof
WO2018154118A3 (en) Aromatic compounds which enhance notch signaling, for use in therapy
MX2023009723A (es) Inhibidores de tyk2 y sus usos.
MX2024007933A (es) Anilinas de 2-pirazol y analogos relacionados para inhibir yap/taz-tead.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
PH12020551179A1 (en) Methods for treating mitochondrial disorder